Back to Search Start Over

Pan-cancer Genomic Analysis of AXL Mutations Reveals a Novel, Recurrent, Functionally Activating AXL W451C Alteration Specific to Myxofibrosarcoma.

Authors :
Williams EA
Vegas I
El-Senduny FF
Zhang J
Mata DA
Hiemenz MC
Hughes SR
Sa BC
Kraft GP
Gorbatov N
Foley-Peres K
Sanchez EZ
Milikowski C
Williams KJ
Ross JS
Kurzrock R
Montgomery EA
Lombard DB
Kumar S
Source :
The American journal of surgical pathology [Am J Surg Pathol] 2024 Jun 01; Vol. 48 (6), pp. 699-707. Date of Electronic Publication: 2024 Feb 19.
Publication Year :
2024

Abstract

Myxofibrosarcoma (MFS) is a common soft tissue sarcoma of the elderly that typically shows low tumor mutational burden, with mutations in TP53 and in genes associated with cell cycle checkpoints ( RB1 , CDKN2A ). Unfortunately, no alterations or markers specific to MFS have been identified and, as a consequence, there are no effective targeted therapies. The receptor tyrosine kinase AXL, which drives cellular proliferation, is targetable by new antibody-based therapeutics. Expression of AXL messenger RNA is elevated in a variety of sarcoma types, with the highest levels reported in MFS, but the pathogenic significance of this finding remains unknown. To assess a role for AXL abnormalities in MFS, we undertook a search for AXL genomic alterations in a comprehensive genomic profiling database of 463,546 unique tumors (including 19,879 sarcomas, of which 315 were MFS) interrogated by targeted next-generation DNA and/or RNA sequencing. Notably, the only genomic alterations recurrent in a specific sarcoma subtype were AXL W451C (n = 8) and AXL W450C (n = 2) mutations. The tumors involved predominantly older adults (age: 44 to 81 [median: 72] y) and histologically showed epithelioid and spindle-shaped cells in a variably myxoid stroma, with 6 cases diagnosed as MFS, 3 as undifferentiated pleomorphic sarcoma (UPS), and 1 as low-grade sarcoma. The AXL W451C mutation was not identified in any non-sarcoma malignancy. A review of publicly available data sets revealed a single AXL W451C-mutant case of UPS that clustered with MFS/UPS by methylation profiling. Functional studies revealed a novel activation mechanism: the W451C mutation causes abnormal unregulated dimerization of the AXL receptor tyrosine kinase through disulfide bond formation between pairs of mutant proteins expressing ectopic cysteine residues. This dimerization triggers AXL autophosphorylation and activation of downstream ERK signaling. We further report sarcomas of diverse histologic subtypes with AXL gene amplifications, with the highest frequency of amplification identified in MFS cases without the W451C mutation. In summary, the activating AXL W451C mutation appears highly specific to MFS, with a novel mechanism to drive unregulated signaling. Moreover, AXL gene amplifications and messenger RNA overexpression are far more frequent in MFS than in other sarcoma subtypes. We conclude that these aberrations in AXL are distinct features of MFS and may aid diagnosis, as well as the selection of available targeted therapies.<br />Competing Interests: Conflicts of Interest and Source of Funding: E.A.W., D.A.M., M.C.H., and J.S.R. are employees/consultants of Foundation Medicine, Inc., a wholly-owned subsidiary of Roche Holdings, Inc. and Roche Finance Ltd.; these employees have an equity interest in an affiliate of these Roche entities. For the remaining authors, none were declared.<br /> (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)

Details

Language :
English
ISSN :
1532-0979
Volume :
48
Issue :
6
Database :
MEDLINE
Journal :
The American journal of surgical pathology
Publication Type :
Academic Journal
Accession number :
38369783
Full Text :
https://doi.org/10.1097/PAS.0000000000002191